指南与共识膀胱癌与上尿路尿路上皮癌

WHO1973与WHO2004/2016分级系统在原发性Ta/T1非肌层浸润性膀胱癌中的预后价值:欧洲泌尿外科学会NMIBC指南委员会多中心研究

Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.
指南 / 共识 · Eur Urol Oncol · 2021-01-08

该研究基于17中心5145例原发性Ta/T1 NMIBC患者个体数据,比较WHO1973与WHO2004/2016分级系统的预后价值。中位随访3.9年,两种系统均不能预测复发,但WHO1973对进展的预后价值高于WHO2004/2016(p<0.001 vs p=0.067)。四层组合(LG/G1、LG/G2、HG/G2、HG/G3)5年进展率分别为1.4%、3.8%、7.7%、18.8%,支持当前EAU指南推荐同时使用两种系统。

要点

  • 两种WHO分级系统均不能预测复发,但可预测进展。
  • WHO1973对进展的预后价值高于WHO2004/2016。
  • 四层组合将G2分为LG/G2和HG/G2,进展风险不同,支持指南推荐同时使用两种系统。

核心结论

  • 两种分级系统均能预测进展但不能预测复发,WHO1973对进展的预后价值高于WHO2004/2016。
  • 四层组合(LG/G1、LG/G2、HG/G2、HG/G3)将G2患者分为预后不同的两个亚组,优于单一系统,支持EAU指南推荐同时使用两种系统。

研究设计与样本

  • 多中心回顾性研究,收集1990至2019年17个中心5145例原发性Ta/T1 NMIBC患者的个体数据,中位随访3.9年。

主要发现

  • 中位年龄68岁,3292例(64%)为Ta肿瘤。
  • 两种分级系统均不能预测复发。
  • 四层组合5年进展率:LG/G1为1.4%,LG/G2为3.8%,HG/G2为7.7%,HG/G3为18.8%(log-rank p<0.001)。
  • 多变量分析中WHO1973是进展的显著预后因素(p<0.001),WHO2004/2016不显著(p=0.067)。
  • WHO1973、WHO2004及两者组合对进展的C-index分别为0.71、0.67、0.73。

关键数值与推荐

  • 四层组合的5年进展率分别为1.4%、3.8%、7.7%、18.8%(log-rank p<0.001)。
  • 多变量分析中WHO1973对进展的p<0.001,WHO2004/2016的p=0.067。
  • C-index:WHO1973为0.71,WHO2004为0.67,组合为0.73。

临床怎么用

  • 临床应同时使用WHO1973和WHO2004/2016分级系统,利用四层组合(LG/G1、LG/G2、HG/G2、HG/G3)评估进展风险。
  • 对于WHO1973 G2患者,应结合WHO2004/2016分级进一步分为低级别和高级别以指导预后判断。

局限性

  • 原文未明确报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the current European Association of Urology (EAU) non-muscle-invasive bladder cancer (NMIBC) guideline, two classification systems for grade are advocated: WHO1973 and WHO2004/2016. OBJECTIVE: To compare the prognostic value of these WHO systems. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5145 primary Ta/T1 NMIBC patients from 17 centers were collected between 1990 and 2019. The median follow-up was 3.9 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariate and multivariable analyses of WHO1973 and WHO2004/2016 stratified by center were performed for time to recurrence, progression (primary endpoint), cystectomy, and duration of survival, taking into account age, concomitant carcinoma in situ, gender, multiplicity, tumor size, initial treatment, and tumor stage. Harrell's concordance (C-index) was used for prognostic accuracy of classification systems. RESULTS AND LIMITATIONS: The median age was 68 yr; 3292 (64%) patients had Ta tumors. Neither classification system was prognostic for recurrence. For a four-tier combination of both WHO systems, progression at 5-yr follow-up was 1.4% in low-grade (LG)/G1, 3.8% in LG/G2, 7.7% in high grade (HG)/G2, and 18.8% in HG/G3 (log-rank, p < 0.001). In multivariable analyses with WHO1973 and WHO2004/2016 as independent variables, WHO1973 was a significant prognosticator of progression (p < 0.001), whereas WHO2004/2016 was not anymore (p = 0.067). C-indices for WHO1973, WHO2004, and the WHO systems combined for progression were 0.71, 0.67, and 0.73, respectively. Prognostic analyses for cystectomy and survival showed results similar to those for progression. CONCLUSIONS: In this large prognostic factor study, both classification systems were prognostic for progression but not for recurrence. For progression, the prognostic value of WHO1973 was higher than that of WHO 2004/2016. The four-tier combination (LG/G1, LG/G2, HG/G2, and HG/G3) of both WHO systems proved to be superior, as it divides G2 patients into two subgroups (LG and HG) with different prognoses. Hence, the current EAU-NMIBC guideline recommendation to use both WHO classification systems remains correct. PATIENT SUMMARY: At present, two classification systems are used in parallel to grade non-muscle-invasive bladder tumors. Our data on a large number of patients showed that the older classification system (WHO1973) performed better in terms of assessing progression than the more recent (WHO2004/2016) one. Nevertheless, we conclude that the current guideline recommendation for the use of both classification systems remains correct, since this has the advantage of dividing the large group of WHO1973 G2 patients into two subgroups (low and high grade) with different prognoses.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. van Rhijn BWG, Hentschel AE, Bründl J, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol. 2021. PMID: 33423944. doi:10.1016/j.euo.2020.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。